Loading market dashboard
Organon & Co.
OGNHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 2, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Organon & Co. ("Organon" or the "Company") (NYSE - OGN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Sun Pharmaceutical Industries Limited for $14.00 per share in an all-cash transaction with an enterprise valuation of $11.75 billion. The investigation concerns whether the Organon Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
VANCOUVER, BC / ACCESS Newswire / May 26, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to report record revenue and after-tax profit for the three-month period ended March 31, 2026. Q1-2026 Highlights All figures are stated in Canadian dollars unless otherwise noted.
Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, Organon Asia Pacific Cluster, met at Organon's Malaysia office to discuss the expansion of Hanmi's combination therapies into the Southeast Asian market. SEOUL, South Korea, May 21, 2026 (GLOBE NEWSWIRE) -- Hanmi Pharmaceutical announced that it has signed a supply agreement with global healthcare company Organon to export three combination medicines for the Malaysian and Philippine markets, expanding the companies' partnership in Southeast Asia.
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data acros
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to present 8 abstracts on affordability, access and adoption across women's health, biosimilar and general medicines portfolio at ISPOR 2026.
VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce the appointment of Mr. Chad Wells to the Company's Board of Directors.
BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith. com) at 855-576-4847.
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Organon (OGN) came out with quarterly earnings of $0.71 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $1.02 per share a year ago.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue in $ millions Q1 2026 Q1 2025 VPY VPY ex-FX Women's Health $ 389 $ 463 (16)% (19)% General Medicines Biosimilars 173 141 23% 21% Established Brands 880 887 (1)% (7)% Other (1) 18 22 (15)% (21)% Revenue $ 1,460 $ 1,513 (4)% (9)% Totals may not foot due to rounding.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 earnings conference call previously scheduled for May 7, 2026. The cancellation is the result of the company's April 26, 2026 announcement that it has entered into an agreement under which Sun Pharmaceutical Industries Limited will acquire Organon. Organon will issue.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Organon & Co. (NYSE: OGN) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Organon will receive $14.00 in cash for each share of Organon that they own. KSF is seeking to determine whether this consideration and the process that led to it.
VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / (TSX:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to report record revenue and after-tax profit for the year ended December 31, 2025. Fiscal 2025 Year End Highlights All figures are stated in Canadian dollars unless otherwise noted.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation.
Expand NYSE: OGN Organon & Co. Today's Change (16.87%) $1.90 Current Price $13.16 Key Data Points Market Cap $2.9B Day's Range $13.15 - $13.24 52wk Range $5.69 - $13.24 Volume 134M Avg Vol 5.8M Gross Margin 53.59% Dividend Yield 0.71% Organon (OGN +16.87%), a women's health therapies specialist, closed Monday at $13.16, up 16.87%. The stock is jumping after premarket news that Sun Pharmaceutical Industries agreed to acquire Organon in an all-cash deal.
OGN stock soars as Sun Pharma strikes $11.75B all-cash deal, aiming to expand biosimilars reach and boost global pharma standing.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of Organon & Co. (NYSE: OGN) breached their fiduciary duties in connection with the proposed sale of the company to Sun Pharmaceutical.
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Organon & Co. (NYSE: OGN ) related to its sale to Sun Pharmaceuticals Industries Limited. Under the terms of the proposed transaction, Organon shareholders will receive $14.00 per share in cash. Is it a fair deal?
Top insights from the latest market news from Monday, April 27, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
Organon (OGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Stock futures are struggling this morning as investors await Magnificent Seven earnings and the Fed meeting
U.S. stock futures fell on Monday, following Friday's mixed close. Futures of the major benchmark indices were lower. This week, investors will be closely watching the Federal Reserve's meeting to gauge how the central bank is navigating interest rates amid the ongoing U.S.-Iran conflict.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Organon & Co. (NYSE: OGN) to Sun Pharmaceutical Industries Limited for $14.00 per share.Halper Sadeh encourages Organon shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whether Organon and its board of directors viol.
India's Sun Pharmaceutical Industries agrees to buy the women's health company for $14 a share in an all-cash deal.
MILWAUKEE, April 27, 2026 /PRNewswire/ -- Ademi LLP is investigating Organon (NYSE: OGN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Sun Pharma. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
Organon and Co. has agreed to be acquired by Sun Pharmaceutical Industries in an all-cash deal valued at $11.75 billion, offering shareholders a 103% premium and marking a major step in Sun Pharma's global expansion into women's health and biosimilars.
In one of the biggest outbound acquisitions ever attempted by an Indian company, Sun Pharmaceutical Industries has decided to buy Organon & Co. for $14 a share in an all-cash deal valued at $11.8 billion The logic of the deal is easy to state and harder to execute as Sun is not buying a fast-growing asset, but a scaled global platform with meaningful cash flow, a large commercial footprint and a huge debt load. Sun is planning to expand in women's health, biosimilars and innovative medicines, while Organon brings more than 70 products across women's health and general medicines in 140 countries.
Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion. Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share.
Sun Pharma has offered to pay $14.00 a share in an all-cash deal.
Sun Pharmaceutical Industries will acquire Organon & Co in an all‑cash deal, valuing the U.S. drugmaker at about $11.75 billion, the companies said in a joint statement on Sunday.
MUMBAI, India & JERSEY CITY, N.J.--(BUSINESS WIRE)--Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of U.
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The latest trading day saw Organon (OGN) settling at $9.33, representing a +1.3% change from its previous close.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will release its first quarter 2026 financial results and host conference call on May 7, 2026.
JERSEY CITY, N.J.--(BUSINESS WIRE)--VTAMA was the only steroid-free topical AAD found supported by high certainty of evidence across all severities in children 2 years and older with AD.
In the latest trading session, Organon (OGN) closed at $8.54, marking a -3.28% move from the previous day.
An index measuring market sentiment based on fear and greed showed a slight increase in fear levels on Friday.
Shares of Organon (OGN) surged sharply on Friday after a report indicated that Sun Pharmaceutical Industries had submitted a binding $12 billion all-cash offer
Citing people familiar with the matter, the Economic Times reported that Sun Pharma has completed an extensive due diligence process spanning more than three months.
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon shares are popping Friday on signs of a takeover deal.
Lumentum and Coherent were gaining on signs of strong artificial-intelligence hardware demand, while Organon was boosted by a takeover report.
XWELL (NASDAQ: XWEL - Get Free Report) and Organon and Co. (NYSE: OGN - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability. Volatility and Risk XWELL has a beta
VANCOUVER, BC / ACCESS Newswire / April 9, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce an update to the Mineral Reserve and Resource estimates on the Ermitaño concession within First Majestic Silver Corp.'s ("First Majestic") Santa Elena gold-silver mine in Sonora, Mexico. Orogen holds a cash-flowing 2% net smelter return ("NSR") royalty on 167 square kilometres of prospective ground at Ermitaño.1,2,3 Highlights of the 2025 Resource and Reserve Update1 Total Measured and Indicated Resources of 7.13 million tonnes containing 380,000 ounces of gold at 1.39 grams per tonne ("g/t") and 8.9 million ounces of silver at 32 g/t Total Inferred Resources of 11.52 million tonnes containing 670,000 ounces of gold at 1.80 g/t and 24.2 million ounces of silver at 65 g/t Measured and Indicated Resources increased year-over-year by 26% for gold and 42% for silver while Inferred Resources increased by 63% for gold and 133% for silver The increases in Measured and Indicated and Inferred Resources were primarily driven by lower cutoff values resulting from updated metal price guidance, infill drilling converting Inferred Resources to Measured and Indicated Resources, and the expansion of the Navidad vein system Paddy Nicol, Orogen's CEO commented, "Exploration and mineral resource expansion at Ermitaño has continued to deliver strong results over 2025.
In the most recent trading session, Organon (OGN) closed at $6.05, indicating a -4.87% shift from the previous trading day.
SG Americas Securities LLC lifted its position in Organon and Co. (NYSE: OGN) by 74.6% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 276,086 shares of the company's stock after buying an additional 117,962 shares during the period. SG
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In the latest trading session, Organon (OGN) closed at $5.84, marking a -3.47% move from the previous day.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's VTAMA (tapinarof) cream, 1% new Phase 3 pooled data analysis shows early and consistent skin clearance and itch improvements for AD patients.
VANCOUVER, BC / ACCESS Newswire / March 24, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") reports preliminary and unaudited financial results for its fourth quarter and year ended December 31, 2025. All figures are stated in Canadian dollars unless otherwise noted.
Sio initiated a new OGN position in the fourth quarter, buying up 3,421,765 shares. The quarter-end position value increased by $24.53 million as a result.
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a potential risk of seizures.
Organon (OGN) closed at $6.23 in the latest trading session, marking a -2.5% move from the prior day.
